Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25251651 | 0.81 | SLC6A3 (0.38) | — | |
| SCHEMBL20745098 | 0.77 | SLC6A3 (0.38) | — | |
| SCHEMBL25839946 | 0.74 | NPSR1 (0.40) | — | |
| SCHEMBL25318682 | 0.68 | P2RX7 (0.32) | — | |
| SCHEMBL25299648 | 0.67 | SLC6A3 (0.35) | — | |
| SCHEMBL12764955 | 0.67 | ACHE (0.38) | — | |
| SCHEMBL21847500 | 0.66 | ALDH1A1 (0.36) | — | |
| SCHEMBL25315269 | 0.65 | KDM4E (0.41) | — | |
| SCHEMBL30135556 | 0.65 | DGAT1 (0.55) | DGAT1 | |
| SCHEMBL1083587 | 0.65 | DGAT1 (0.55) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4620472-A2 | TRICYCLIC PARP1 INHIBITORS AND USES THEREOF | Xinthera, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12421241-B2 | Substituted pyridines as PARP1 inhibitors | XINTHERA, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| EP-4497438-B1 | TRICYCLIC PARP1 INHIBITORS AND USES THEREOF | XINTHERA INC (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-4355749-B1 | TRICYCLIC PARP1 INHIBITORS AND USES THEREOF | XINTHERA INC (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4497438-A2 | TRICYCLIC PARP1 INHIBITORS AND USES THEREOF | Xinthera, Inc. (US) | 2025-01-29 | — | — | EP | disclosed |
| US-20240400569-A1 | SUBSTITUTED PYRIDINES AS PARP1 INHIBITORS | XINTHERA, INC. | 2024-12-05 | — | — | US | disclosed |
| US-12006322-B2 | Substituted pyridines as PARP1 inhibitors | Xin Thera, Inc. (US) | 2024-06-11 | — | — | US | disclosed |
| EP-4355749-A1 | TRICYCLIC PARP1 INHIBITORS AND USES THEREOF | Xinthera, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| US-20240109904-A1 | SUBSTITUTED PYRIDINES AS PARP1 INHIBITORS | XINTHERA, INC. | 2024-04-04 | — | — | US | disclosed |
| US-20230348473-A1 | SUBSTITUTED PYRIDINES AS PARP1 INHIBITORS | XINTHERA, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348473-A1 | SUBSTITUTED PYRIDINES AS PARP1 INHIBITORS | XINTHERA, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348473-A1 | SUBSTITUTED PYRIDINES AS PARP1 INHIBITORS | XINTHERA, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2023212219-A1 | TRICYCLIC PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023212219-A1 | TRICYCLIC PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-11795173-B1 | Substituted pyridines as PARP1 inhibitors | XINTHERA, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795173-B1 | Substituted pyridines as PARP1 inhibitors | XINTHERA, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795173-B1 | Substituted pyridines as PARP1 inhibitors | XINTHERA, INC. (US) | 2023-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348473-A1 | SUBSTITUTED PYRIDINES AS PARP1 INHIBITORS | PARP1, PARP11, PARP12 | DGAT1 2984/4885 |
| US-12421241-B2 | Substituted pyridines as PARP1 inhibitors | PARP1, PARP11, PARP12 | DGAT1 2984/4885 |
| US-20240109904-A1 | SUBSTITUTED PYRIDINES AS PARP1 INHIBITORS | PARP1, PARP11, PARP12 | DGAT1 2984/4885 |
| US-20240400569-A1 | SUBSTITUTED PYRIDINES AS PARP1 INHIBITORS | PARP1, PARP11, PARP12 | DGAT1 2984/4885 |
| US-12006322-B2 | Substituted pyridines as PARP1 inhibitors | PARP1, PARP11, PARP12 | DGAT1 2684/4885 |
| US-11795173-B1 | Substituted pyridines as PARP1 inhibitors | PARP1, PARP11, PARP12 | DGAT1 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.